Ann: Next Science reports FY23 Result, page-6

Their average Q on Q growth rate over the last two years has been 24%. To achieve bottom of the revenue guidance - US$36m revenue, they need to achieve an average Q on Q growth rate for the 24 year of 10%. Based on their projections, this will bring them to cashflow positive before the end of 2024.

IV confirmed that they do not expect to have to raise any further capital. Their biggest unknown in their forecasts would be revenue. The rest is formulaic and or manageable. So given the ease with which they should achieve the bottom of their guidance range, I think that the cashflow projection is likely to be achieved.

To me that will result in a significant rerate of this stock. There are a lot of holders who are also believers in the quality of the product. I am one of those and continue to build my position. I am very excited about the future of this company. I think that IV is doing a way better job than Judith and the results are already showing - particularly the change in target clientele which resulted in a temporary drop in revenue growth and margin. But look how that has turned around and will now benefit the companies performance going forward.